Physician profile
Mark A Hurt
NPI 1891866190
$2,117.30
in general payments reported to CMS, 2019-2025
12 companies · $883 in 2025
The $883 reported for 2025 was more than what 89% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.08 · 2022: $193 · 2023: $234 · 2024: $790 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.73 | 2024-2025 | Spevigo |
| Amgen INC. | $346.75 | 2023-2025 | Otezla, Otezla |
| Organogenesis INC. | $248.56 | 2024-2025 | Puraply Wound Matrix |
| E.R. Squibb & Sons, L.L.C. | $215.83 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $213.06 | 2022-2024 | Libtayo |
| Regeneron Pharmaceuticals, INC. | $134.95 | 2025 | Libtayo |
| Kerecis Limited | $126.07 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Ucb, INC. | $124.29 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $111.47 | 2024 | Vtama |
| Incyte Corporation | $96.94 | 2022 | |
| Galderma Laboratories, L.P. | $92.11 | 2025 | Nemluvio |
| Roche Diagnostics Corporation | $50.54 | 2021-2025 | Benchmark Ultra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hurt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.